Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT04979390
A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: SHR6390、efavirenz
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04973020
- Locations
- 🇨🇳
Xuanwu Hospital Beijing, Capital Medical University, Beijing, Beijing, China
Extension Study of Hetrombopag in Severe Aplastic Anemia
Phase 3
Recruiting
- Conditions
- Treatment-naive Severe Aplastic Anemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT04961710
- Locations
- 🇨🇳
Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis
Phase 3
- Conditions
- Psoriatic Arthritis
- Interventions
- Drug: SHR0302 tablets、PlaceboDrug: Placebo
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 444
- Registration Number
- NCT04957550
- Locations
- 🇨🇳
Peking University Hospital, Beijing, Beijing, China
A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 779
- Registration Number
- NCT04956432
- Locations
- 🇨🇳
RenJi Hospital, Shanghai JiaoTong University School Of Medicine, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
Phase 3
- Conditions
- Acute Vulvovaginal Candidiasis
- Interventions
- Drug: SHR8008 capsule
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 322
- Registration Number
- NCT04956419
- Locations
- 🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China
SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
Phase 2
- Conditions
- Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
- Interventions
- Drug: Gemcitabine-OxaliplatinDrug: SHR1459 ；YY-20394
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT04948788
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School, Shanghai, Shanghai, China
To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects
Phase 1
Completed
- Conditions
- Thrombosis
- Interventions
- Drug: Aspirin、clopidogrel、placebo or SHR2285Drug: Aspirin、ticagrelor、placebo or SHR2285
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT04945616
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
Phase 3
Active, not recruiting
- Conditions
- Cervical Cancer
- Interventions
- Drug: platinum-based chemotherapy
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 443
- Registration Number
- NCT04906993
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Relative Bioavailability Study of SHR3680
Phase 1
- Conditions
- Healthy Male Subjects
- Interventions
- Drug: test SHR3680 tabletsDrug: reference SHR3680 tablets
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04903158
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guanzhou, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath